Form 4: Maze Therapeutics Director Sells Shares

Catherine A. Sohn, a director at Maze Therapeutics, Inc., executed pre-planned sales of common stock totaling 29,413 shares following option exercises.

Summary

• Catherine A. Sohn, a director of Maze Therapeutics, Inc., engaged in multiple transactions involving the company's common stock.
• On January 6, 2026, Sohn exercised options to acquire 2,493 shares at $10.42 per share and subsequently sold all 2,493 shares at a weighted average price of $38.616.
• On January 7, 2026, Sohn exercised options to acquire a total of 26,920 shares (20,744 + 2,895 + 3,281) at $10.42 per share.
• Immediately following these exercises on January 7, 2026, Sohn sold all 26,920 acquired shares at a weighted average price of $39.1079.
• These transactions were conducted pursuant to a Rule 10b5-1 pre-planned trading arrangement.

Sentiment

Score: 6

Explanation: The filing indicates a director monetizing vested equity compensation through pre-planned transactions, which is a neutral event. The significant gain realized by the director could be seen as positive for the individual but does not inherently change the company's operational outlook.

Positives

• The director realized significant gains from exercising options at $10.42 and selling shares at prices ranging from $38.61 to $39.85.
• The transactions were pre-planned under a Rule 10b5-1 plan, indicating a structured approach to equity management and reducing concerns about opportunistic selling.

Negatives

• The director's sale of all exercised shares could be interpreted as a reduction in direct equity exposure, though this is a common practice for monetizing vested equity compensation.

Future Outlook

NA

Industry Context

This Form 4 filing details routine insider transactions by a director, which is a common occurrence in publicly traded companies, particularly for equity compensation plans. It does not provide broader industry context.

Stakeholder Impact

• Shareholders may observe a director monetizing equity, which is a normal part of compensation. The transactions were pre-planned, reducing concerns about opportunistic selling.

Key Dates

Recommendation

The filing details routine insider transactions (option exercises and sales) by a director under a pre-planned Rule 10b5-1 arrangement. These transactions are expected and do not provide new fundamental information about Maze Therapeutics' operational performance, strategic direction, or financial health that would warrant a change in investment recommendation. The director's monetization of vested equity is a common practice and does not signal a change in confidence in the company's long-term prospects.

Keywords

Maze Therapeutics, MAZE, SEC Form 4, Insider Trading, Stock Option Exercise, Share Sale, Director Transactions, Rule 10b5-1